In Vitro Immune Synapse System Using Homogeneous Pig Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro cell evaluation platforms rely on cells from mice or commercial lines, which are limited by species specificity and immune rejection issues, and primary cells from these sources have low credibility in simulating immune responses, making them inadequate for evaluating vaccine antigens and adjuvants.
Innovation Solution
An in vitro immune synapse system using antigen-presenting cells and specific T-cell subtypes from the same individual pig, such as regulatory T cells, killer cells, and helper T cells, which are co-cultured with a test sample to assess immunogenicity and immunostimulatory effects, replacing animal experimentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If cells from mice or commercial cell lines are used in in vitro evaluation platforms, then sufficient cell quantity is available, but the evaluation results cannot replace animal experimentation due to species specificity and low credibility in simulating immune responses
Solution Approach 1:
The patent changes the species parameter from mice to pigs, selecting pigs as the source of primary immune cells. This parameter change allows the system to maintain species-specific immune response characteristics while obtaining sufficient cell quantities for evaluation, thereby resolving the contradiction between cell quantity and credibility of immune response simulation
Solution Approach 2:
The patent creates an in vitro immune synapse system that copies the in vivo immune response environment. By establishing co-culture systems with antigen-presenting cells and T cells from the same pig individual, the system replicates physiological immune interactions, enabling reliable evaluation that can replace animal experimentation while maintaining sufficient cell quantities
2Quantity of substance
If immune cells are collected from different individual mice to obtain sufficient cell quantity, then enough cells are available for testing, but immune rejections occur due to co-culture of cells from different individuals and species
Solution Approach 1:
The patent applies homogeneity by using immune cells from the same pig individual for both antigen-presenting cells and T cell subtypes. This ensures genetic and immunological compatibility between co-cultured cells, preventing immune rejection while maintaining sufficient cell quantities for comprehensive evaluation
3Adaptability or versatility
If primary cells from mice are used, then species-specific immune responses can be studied, but the credibility of immune response simulation is low compared to normal cells
Solution Approach 1:
The patent changes the species parameter from mice to pigs and uses primary cells from the same individual for all immune cell types. This parameter change maintains species-specific immune response characteristics while improving credibility by eliminating immune rejection and ensuring physiological relevance, thereby resolving the contradiction between adaptability and reliability
Data Source
AI summary
The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.